Loading people...
Adam Cotton is an Associate at the Novartis Venture Fund based in Cambridge, Massachusetts. In his current role, he serves as a board observer for five biotechnology startups, including GentiBio, Mediar Therapeutics, and three stealth-mode companies. Prior to joining the venture capital sector, he was the scientific co-founder of Epi Biologics and contributed to strategy development for an RA Capital incubator company. He also assisted in the corporate transition of Rezo Therapeutics from academic laboratories into a standalone commercial entity. Cotton holds a PhD in Chemistry and Chemical Biology from the University of California, San Francisco, a BA in Chemistry from Harvard University, and an MBA from the University of New Mexico. His professional focus centers on early-stage therapeutic investments, leveraging his academic expertise in antibody engineering and chemical biology to evaluate emerging life sciences platforms.
Adam Cotton is an integral Associate at Novartis Venture Fund, a leading corporate venture capital firm dedicated to investing in innovative companies that have the potential to transform healthcare. In his role, Adam is deeply involved in the entire investment lifecycle, from initial sourcing and due diligence to portfolio management and strategic support for portfolio companies. He works closely with the fund's partners and investment teams to identify cutting-edge scientific advancements and entrepreneurial teams poised to make a significant impact in medicine.
Novartis Venture Fund, where Adam Cotton contributes his expertise, is known for its strategic investments across various therapeutic areas and technology platforms. Adam's investment focus aligns with the fund's broader mandate, encompassing areas such as novel therapeutics, gene and cell therapies, precision medicine, digital health solutions, and medical devices. He is particularly interested in early-stage companies that are developing disruptive technologies or approaches to address high unmet medical needs, leveraging his analytical skills to assess scientific merit, market potential, and team capabilities.
While specific details of Adam Cotton's career background are not extensively publicized, individuals in his position typically possess a strong foundation in life sciences, often with advanced degrees in biology, chemistry, or medicine, complemented by experience in venture capital, business development, or scientific research. This multidisciplinary background is essential for navigating the complex landscape of biotech and healthcare innovation, allowing him to effectively evaluate the scientific rigor and commercial viability of potential investments. His work at Novartis Venture Fund places him at the forefront of healthcare innovation, contributing to the strategic growth of the fund's diverse portfolio.
Adam's contributions help Novartis Venture Fund fulfill its mission of fostering innovation outside of Novartis's internal R&D. By supporting promising startups, he helps accelerate the development of new medicines and technologies that could ultimately benefit patients worldwide. While specific notable investments directly attributed to an Associate are often part of a broader team effort, Adam Cotton plays a vital role in the discovery and nurturing of the next generation of healthcare leaders and technologies within the fund's portfolio. His dedication to identifying and supporting groundbreaking ventures underscores his commitment to advancing medical science and improving patient outcomes.
Adam Cotton is an Associate at Novartis Venture Fund, a corporate venture capital firm. He is involved in identifying, evaluating, and supporting early-stage companies in the life sciences sector that are developing innovative healthcare solutions.
Adam Cotton's investment focus at Novartis Venture Fund includes innovative biotech, novel therapeutics, gene and cell therapies, precision medicine, digital health solutions, and medical devices. He targets early-stage companies with disruptive technologies addressing unmet medical needs.
Adam Cotton works as an Associate at Novartis Venture Fund, which is the corporate venture capital arm of Novartis, dedicated to investing in groundbreaking healthcare and life sciences companies.
